Jeito Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsSanofi VenturesSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsVida VenturesYsios Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.